Mesoblast to Showcase Ryoncil Sales and $Multi-Billion Pipeline at April 8 R&D Day
Mesoblast will host its inaugural R&D Day on April 8, 2026 in New York City with a live webcast from 8:00am to 11:00am EST featuring presentations on corporate strategy, commercialization of Ryoncil and its multi-billion-dollar pipeline in inflammatory pain and cardiovascular disease. The company will unveil new cellular-medicine technology designed to drive future innovation and growth.
1. Event Logistics
Mesoblast’s inaugural R&D Day will be held on April 8, 2026 in New York City, with a live webcast from 8:00am to 11:00am EST. A replay of the presentations will be made available on the company’s website shortly after the event concludes.
2. Agenda and Presenters
Senior leadership and key opinion leaders will cover Mesoblast’s corporate strategy, discuss the successful commercialization of Ryoncil®, and outline upcoming milestones across its inflammatory pain and cardiovascular disease programs.
3. Pipeline and Technology
The company will highlight its multi-billion-dollar pipeline opportunities and unveil a new cellular-medicine technology platform intended to power the next era of allogeneic therapies.
4. Access and Participation
Investors and stakeholders can access the live webcast via Mesoblast’s website or the provided webcast link, ensuring real-time participation in the company’s strategic presentations.